Fina Biosolutions LLC announced today it has reached agreement with PATH, a global organization focused on solving some of the world’s most pressing health challenges, under which PATH will provide funding and technical support for the clinical manufacture of FinaBio’s CRM₁₉₇, known commercially as EcoCRM^®. As consideration for this support, FinaBio has licensed PATH its CRM₁₉₇, a key component in conjugate vaccines. Under the license, PATH receives non-exclusive rights to EcoCRM^® for infectious disease vaccines sold to, or for supply to, low-income countries.

Click here to read more.